Cowen reiterated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Monday, AnalystRatings.com reports.
A number of other research analysts also recently commented on KRYS. Zacks Investment Research raised shares of Krystal Biotech from a sell rating to a hold rating in a research note on Wednesday, April 10th. ValuEngine raised shares of Krystal Biotech from a buy rating to a strong-buy rating in a research note on Friday, March 1st. Chardan Capital upped their price objective on shares of Krystal Biotech from $50.00 to $57.50 and gave the company a buy rating in a research note on Tuesday, March 12th. Finally, HC Wainwright reaffirmed a buy rating and set a $32.00 price objective on shares of Krystal Biotech in a research note on Tuesday, January 15th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of $36.90.
NASDAQ:KRYS opened at $32.22 on Monday. The stock has a market capitalization of $469.14 million, a price-to-earnings ratio of -33.22 and a beta of 0.59. Krystal Biotech has a 12-month low of $9.90 and a 12-month high of $36.89.
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. As a group, equities research analysts predict that Krystal Biotech will post -1.46 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Knott David M acquired a new position in shares of Krystal Biotech during the 4th quarter valued at about $31,000. JPMorgan Chase & Co. increased its position in Krystal Biotech by 445.3% during the 1st quarter. JPMorgan Chase & Co. now owns 6,615 shares of the company’s stock worth $218,000 after purchasing an additional 5,402 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in Krystal Biotech during the 4th quarter worth approximately $159,000. California Public Employees Retirement System acquired a new stake in Krystal Biotech during the 1st quarter worth approximately $263,000. Finally, TD Asset Management Inc. acquired a new stake in Krystal Biotech during the 1st quarter worth approximately $268,000. 43.11% of the stock is owned by institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: Bollinger Bands
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.